Skip to content

Arno Therapeutics, Inc: 10-Q filed 2014-08-14

What Arno Therapeutics, Inc reported in its quarterly report filed 2014-08-14 (fiscal Q2 2014): 27 published measures, 101 facts as tagged in accession 0001144204-14-050193.

This filing

Form
10-Q (quarterly report)
Filed
2014-08-14
Fiscal period
fiscal Q2 2014
Accession
0001144204-14-050193 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Arno Therapeutics, Inc filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2014-06-3015,947,781USD
At 2013-12-3126,882,644USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2014-06-3023,364,886USD
At 2013-12-3139,765,970USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2014-06-30-7,417,105USD
At 2013-12-31-12,883,326USD
At 2012-12-31-12,265,832USD
At 2011-12-311,355,639USD
At 2010-12-318,435,820USD
At 2005-07-310USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2014-06-3015,844,600USD
At 2013-12-3126,774,203USD
At 2013-06-304,554,390USD
At 2012-12-3110,943,437USD
At 2005-07-310USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2014-04-01 to 2014-06-303,494,633USD91
2014-01-01 to 2014-06-303,048,192USD181
2005-08-01 to 2014-06-30-86,509,565USD3256
2013-01-01 to 2013-12-31-39,656,975USD365
2013-04-01 to 2013-06-30-11,304,830USD91
2013-01-01 to 2013-06-30-12,238,718USD181
2012-01-01 to 2012-12-31-14,387,782USD366
2011-01-01 to 2011-12-31-7,909,113USD365
2005-08-01 to 2010-12-31-27,603,887USD1979

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2014-01-01 to 2014-06-3020,097USD181
2005-08-01 to 2014-06-30120,271USD3256
2013-01-01 to 2013-06-300USD181

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2014-04-01 to 2014-06-3020,370,331shares91
2014-01-01 to 2014-06-3020,370,331shares181
2013-04-01 to 2013-06-304,814,822shares91
2013-01-01 to 2013-06-304,684,384shares181

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2014-04-01 to 2014-06-3024,802,522shares91
2014-01-01 to 2014-06-3024,804,963shares181
2013-04-01 to 2013-06-304,814,822shares91
2013-01-01 to 2013-06-304,684,384shares181

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2014-04-01 to 2014-06-300.17USD/shares91
2014-01-01 to 2014-06-300.15USD/shares181
2013-04-01 to 2013-06-30-2.35USD/shares91
2013-01-01 to 2013-06-30-2.61USD/shares181

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2014-04-01 to 2014-06-300.14USD/shares91
2014-01-01 to 2014-06-300.12USD/shares181
2013-04-01 to 2013-06-30-2.35USD/shares91
2013-01-01 to 2013-06-30-2.61USD/shares181

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2014-06-3025,256USD
At 2013-12-3111,720USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2014-01-01 to 2014-06-302,418,029USD181
2005-08-01 to 2014-06-307,546,020USD3256
2013-01-01 to 2013-06-30699,298USD181

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2014-04-01 to 2014-06-30-5,763,503USD91
2014-01-01 to 2014-06-30-11,927,271USD181
2005-08-01 to 2014-06-30-75,055,640USD3256
2013-04-01 to 2013-06-30-3,409,767USD91
2013-01-01 to 2013-06-30-7,254,635USD181

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2014-06-3015,912,070USD
At 2013-12-3126,860,469USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2014-04-01 to 2014-06-300USD91
2014-01-01 to 2014-06-300USD181
2005-08-01 to 2014-06-3026,190,285USD3256
2013-04-01 to 2013-06-301,858,887USD91
2013-01-01 to 2013-06-304,017,608USD181

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2014-06-302,483,485USD
At 2013-12-313,901,089USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2014-06-301,361,737USD
At 2013-12-312,941,998USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2014-04-01 to 2014-06-305,763,503USD91
2014-01-01 to 2014-06-3011,927,271USD181
2005-08-01 to 2014-06-3075,055,640USD3256
2013-04-01 to 2013-06-303,409,767USD91
2013-01-01 to 2013-06-307,254,635USD181

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2014-04-01 to 2014-06-304,083,398USD91
2014-01-01 to 2014-06-308,518,114USD181
2005-08-01 to 2014-06-3058,839,691USD3256
2013-04-01 to 2013-06-302,741,756USD91
2013-01-01 to 2013-06-305,734,787USD181

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2014-06-3020,370,331shares
At 2013-12-3120,370,331shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2014-06-3079,086,995USD
At 2013-12-3176,668,966USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2014-06-3058,633USD
At 2013-12-3186,266USD

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2014-04-01 to 2014-06-301,680,105USD91
2014-01-01 to 2014-06-303,409,157USD181
2005-08-01 to 2014-06-3016,215,949USD3256
2013-04-01 to 2013-06-30668,011USD91
2013-01-01 to 2013-06-301,519,848USD181

Other nonoperating income or expense

Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.

PeriodValueUnitDays
2014-04-01 to 2014-06-309,244,792USD91
2014-01-01 to 2014-06-3014,950,603USD181
2005-08-01 to 2014-06-3014,279,643USD3256
2013-04-01 to 2013-06-30-6,039,108USD91
2013-01-01 to 2013-06-30-973,467USD181

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2014-04-01 to 2014-06-309,258,136USD91
2014-01-01 to 2014-06-3014,975,463USD181
2005-08-01 to 2014-06-30-11,453,925USD3256
2013-04-01 to 2013-06-30-7,895,063USD91
2013-01-01 to 2013-06-30-4,984,083USD181

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2014-01-01 to 2014-06-300USD181
2005-08-01 to 2014-06-3037,115,377USD3256
2013-01-01 to 2013-06-300USD181

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2014-01-01 to 2014-06-30-1,580,261USD181
2005-08-01 to 2014-06-301,361,737USD3256
2013-01-01 to 2013-06-30627,612USD181

Inspect the source

Entity
Arno Therapeutics, Inc / CIK 0001195116
Captured
SEC response SHA-256
daf59b1b66be981617a28a70398e42d86562bef04d5c645d4ccff16477481049

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001195116.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))